News

Deal Announcements

Esperance Pharma Lands First Venture Capital Funding

Monday, February 9, 2009 5:38:00 AM PDT | VentureDeal Staff
Baton Rouge, Louisiana  --  Anticancer drug company Esperance Pharmaceuticals has raised $5 million in additional series A venture capital investment.

Esperance is developing a class of drugs that attempt to selectively kill cancer cells, while leaving normal cells unharmed.

VCE Capital is one of the company's existing investors. The company did not disclose how it would use the funding proceeds.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1